[Four years of clinical experience with the cardio-eurhythmic action of verapamil in intravenous administration].
Personal clinical experience using Verapamil intravenously in 200 patients with a number of arrhythmia conditions is reported. The effectiveness of the drug in controlling supraventricular paroxysmal tachycardia and high ventricular frequency atrial fibrillation in particular is pointed out. Good results were also obtained in atrial flutter, in sinus tachycardia, in extrasystole conditions and, at times, in ventricular paroxysmal tachycardia. Clinical experience limits contraindications to atrioventricular block, severe shock, excessive digitalization, and the associated use of beta block substances.
D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001281:Atrial Fibrillation / Q000188:drug therapy; D001282:Atrial Flutter / Q000188:drug therapy; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D007275:Injections, Intravenous; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy; D014693:Ventricular Fibrillation / Q000188:drug therapy; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use*
D014700:Verapamil
Quattro anni di esperienze cliniche sull'azione cardioeuritmizzante del verapamil per somministrazione endovenosa